Answers are grounded in this paper and cite their sources.
In vitro testing demonstrates potent plasmin inhibition and suppressed fibrinolysis in human plasma, suggesting safer alternatives to traditional antifibrinolytics.
= 0.05 nM) inhibitor of the primary serine protease in fibrinolysis, plasmin. This compound displays a million-fold selectivity over other serine proteases in blood, inhibits fibrinolysis in plasma more effectively than the gold-standard therapeutic inhibitor aprotinin, and is a promising candidate for development of highly specific fibrinolysis inhibitors with reduced side effects.
No takes yet. Share an insight, caveat, or question.
Swedberg et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: